Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer


Angelergues A., Maillet D., Flechon A., Ozguroglu M. , Mercier F., Guillot A., ...More

EUROPEAN JOURNAL OF CANCER, vol.50, pp.1602-1609, 2014 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 9
  • Publication Date: 2014
  • Doi Number: 10.1016/j.ejca.2014.03.015
  • Title of Journal : EUROPEAN JOURNAL OF CANCER
  • Page Numbers: pp.1602-1609

Abstract

Background: A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to evaluate the incidence and characteristics of PSA flare on cabazitaxel, and its impact on survival.